Short-term effect of IL-6 inhibition in spondylarthritis.
Daniel
D
Wendling
Marie
M
Bossert
Clément
C
Prati
D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D002097:C-Reactive Protein / Q000032:analysis; D004185:Disability Evaluation; D006801:Humans; D008279:Magnetic Resonance Imaging; D008297:Male; D020127:Recovery of Function; D012720:Severity of Illness Index; D025241:Spondylarthritis / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D016896:Treatment Outcome; D000093242:Interleukin-6 Inhibitors; D015850:Interleukin-6
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D002097:C-Reactive Protein; D000093242:Interleukin-6 Inhibitors; C508600:IL6 protein, human; D015850:Interleukin-6; C502936:tocilizumab